Psychedelics May Help Manage Long COVID-19 Symptoms

We have seen interest in psychedelics increase significantly these last few years, with more studies highlighting the medical benefits these substances possess. Thus far, research has shown that psychedelics such as psilocybin, MDMA and ketamine may help treat mental health conditions, including anxiety, depression, post-traumatic stress disorder and substance-use disorder.

Now, researchers believe that these substances may be useful in the management of long COVID-19 symptoms.

Individuals with long COVID-19 often present with coronavirus symptoms that may last months or even years after the infection. The most common symptoms of long COVID-19 include feeling short of breath, extreme fatigue, muscle aches and loss of smell.

Studies on psychedelics and long COVID aren’t many because psychedelic drugs are still illegal at the federal level, due to their classification as Schedule I substances under the Controlled Substances Act.

But, research is growing, with Dr. Joel Castellanos of the Psychedelics and Health Research Initiative at the University of California-San Diego revealing that he’s heard from many patients with long COVID who have tried psychedelics. Castellanos revealed that one patient who used a psilocybin and MDMA combination to manage their symptoms actually saw improvements in their headaches, fatigue, depression and brain fog.

Dr. Sue Sisley, a psilocybin researcher at Scottsdale Research Institute, has also had patients admit to using psychedelics as long COVID remedies, noting that some did see improvements in their memory, cognitive function and energy. Sisley, who works in a community clinic catering to patients with long COVID, recently advised legislators on a measure that would allocate millions for studies into the therapeutic potential of psilocybin for various conditions, including long COVID.

She believes that psilocybin alleviates symptoms of this condition by encouraging tissue growth and new neuronal connections in the brain and decreasing inflammation in an individual’s body.

Prior studies have suggested that inflammation may be a target for psychedelic treatments. Professor Charles Nichols of pharmacology at the Louisiana State University has discovered, using mouse models, that certain psychedelics have anti-inflammatory effects.

If the same is found to be true in people, Nichols believes that it’s reasonable to think psychedelic drugs could also offer relief to individuals suffering from long COVID-19. It should be noted, however, that at this particular point in time, none of these claims have been proven as no clinical trials have been conducted to ascertain psychedelics’ effectiveness in managing long COVID-19 symptoms.

Individuals are advised to proceed with a lot of caution because psychedelics are potent drugs. This potency is largely the reason why startups such as Compass Pathways PLC (NASDAQ: CMPS) envisage psychedelic treatments being administered in clinical settings only.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050